From January 1, 2024 to March 31, 2024, the company has repurchased 5,574,913 shares, representing 1.39% for CNY 44.65 million. With this, the company has completed the repurchase of 5,574,913 shares, representing 1.39% for CNY 44.65 million under the buyback announced on November 30, 2023.
Chemclin Diagnostics Co., Ltd.
Equities
688468
CNE100005311
Medical Equipment, Supplies & Distribution
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
6.71 CNY | +1.21% |
|
-0.45% | -37.81% |
05-21 | Shareholders to Cut Up to 2% Stake in Chemclin Diagnostics | MT |
05-03 | Chemclin Diagnostics Launches Homegrown Immunodetection Kits | MT |
1st Jan change | Capi. | |
---|---|---|
-37.81% | 367M | |
-2.58% | 8.27B | |
+8.38% | 5.81B | |
+29.76% | 5.58B | |
-15.77% | 3.85B | |
+12.42% | 2.71B | |
-61.85% | 2.56B | |
-7.34% | 2.42B | |
+23.09% | 2.13B | |
-9.25% | 1.77B |
- Stock Market
- Equities
- 688468 Stock
- News Chemclin Diagnostics Co., Ltd.
- Tranche Update on Chemclin Diagnostics Co., Ltd.'s Equity Buyback Plan announced on November 30, 2023.